←
Olivier Elemento26,734 posts
Olivier Elemento avatar✓

Olivier Elemento ✓

@ElementoLab

Director, Englander Institute for Precision Medicine @WCMenglanderIPM, Associate Director @wcmc_ctsc & ICB, Co-Founder @volastratx & @onethreebiotech

◷ Joined January 2012▧ 553 Photos and videos
OpenAI avatar
⟳ Olivier Elemento retweeted
OpenAI@OpenAI·19h

Some of you have been asking very politely. Some of you have just been asking. GPT-6.2 Astra and Sol are now available. Super efficient and built to perform where it counts—the real world. openai.com/index/introducing…

1:59
Memorial Sloan Kettering Cancer Center avatar
⟳ Olivier Elemento retweeted
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·22h

🚨 A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial. The vaccine, galinpepimut-S (GPS), is an “off-the-shelf” vaccine invented by MSK leukemia specialist and physician-scientist Dr. David A. Scheinberg (@DASLab_MSKCC). In the trial of 126 patients, it reduced the risk of death by 41%. Median overall survival was 24.0 months with the vaccine compared with 14.7 months for patients on standard treatments. “These data bring us closer to having the first off-the-shelf vaccine for AML patients." Learn more: bit.ly/4fDoAmS

Post attachment
Memorial Sloan Kettering Cancer Center avatar
⟳ Olivier Elemento retweeted
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·Nov 12

Researchers at MSK have developed a new computational approach to better understand why #Tcells, the immune system’s primary cancer-fighting cells, respond differently to immunotherapies. Led by computational oncologists @bengrbm and @SohrabShah, the team created a statistical model called TCRi that links a T cell’s unique receptor sequence to its biological behavior, helping reveal how these cells recognize and react to cancer. By analyzing more than 167,000 T cells from patients treated with checkpoint inhibitor immunotherapies, the researchers aimed to uncover how a T cell’s genetic identity influences its activity and how those behaviors change during treatment, potentially improving the ability to predict which patients will benefit from immunotherapy. “This approach produces a standardized measurement that lets us compare results across different studies and clinical trials,” Dr. Greenbaum says. “We have a way to learn from this data what a meaningful T cell response to an immunotherapy looks like — or doesn’t.” Learn more about this research: bit.ly/48yVscR

Post attachment
Michael H. Tomasson, MD avatar
⟳ Olivier Elemento retweeted
Michael H. Tomasson, MD@MTomasson·Nov 12

Hugely important paper. First came myeloma: we learned that we can detect precursor lesions years in advance. Now AML, the classic "out of the blue" blood cancer, turns out to have pre-malignant clones detectable years in advance. We'll keep working on cures, but it's time to start thinking about screening and prevention strategies for blood cancers.

1:57
Jamie Blundell avatar
⟳ Olivier Elemento retweeted
Jamie Blundell@jrblundell·Nov 11

How do cancers emerge from healthy tissue? In @Nature today: leukaemia evolving in yearly blood samples up to 15 yrs before AML. First driver by age 20; each new driver multiplies growth 2–3×. A remarkably simple set of mathematical rules recapitulate it. nature.com/articles/s41586-0…

Ethan Mollick avatar
⟳ Olivier Elemento retweeted
Ethan Mollick@emollick·Nov 9

I had early access to Fable 5.2 for a bit & I think it crosses the line into being a sort of Jagged AGI. Here, I have it launch a business, do academic research, hack hardware, build 3D models & more. I think it is a good illustration of limits & powers: oneusefulthing.org/p/fable-5…